INTUITIVE SURGICAL INC
ISRGNasdaqGSMedical Instruments & Supplies • Healthcare
Comprehensive AI Analysis
Strategic AI Analysis for ISRG
Checking whether the approved providers contain enough current financial data for a reliable report.
Summary
Source-linked company research for ISRG
Factor Scorecard
Mechanical 0-100 composites from the displayed inputs. Bands and colours are numerical aids, not security ratings or investment actions.
Latest results at a glance
Insights from the latest company results and reports
Quarterly Earnings Exceed Consensus
Reported EPS of $2.80 per share exceeded the same-quarter consensus estimate of $2.50 for the period ended 2026-06-30.
Revenue Growth Accelerates
Revenue for the quarter ended 2026-06-30 was $2.89bn, up 18.54% from $2.44bn in the same quarter of the prior year.
Net Income Rises Year-Over-Year
Net income for the quarter ended 2026-06-30 was $818.1m, up 24.26% from $658.4m in the quarter ended 2025-06-30.
Gross Margin Expands
Gross margin for the quarter ended 2026-06-30 was 67.78%, wider than the 66.31% recorded for the quarter ended 2025-06-30.
Capital Returns Funded by Cash Flow
Filed free cash flow of $2.491B was 1.09x common-stock repurchases of $2.295B in the fiscal year ended 2025-12-31.
Price Chart
NASDAQ:ISRG via TradingView
Loading TradingView chart...
Overview
Quarterly income statement data isn't available for this company.
No Data
No annual financial data available.
Financial Fundamentals
Growth, quality, valuation, cash generation, and balance-sheet strength.
Growth
TTM revenue plus current, long-term, forward, and accelerating top-line trends.
Earnings
Trailing EPS, current EPS growth, long-term compounding, surprise, and forward expectations.
Profitability
TTM margin and return metrics that reflect pricing power and business quality.
Cash Flow
TTM free cash flow, growth, margin, and operating-cash conversion quality.
Valuation
Metrics ranked by issuer type, financial state, and input quality.
Forward P/E
Forward P/E is the primary lens because positive expected earnings make the next operating period directly assessable.
Financial Health
Latest-quarter liquidity and leverage checks plus TTM interest coverage.
Shareholder Signals
Capital returns and dilution checks sourced from statements and insider filings.
Peer Comparison
| Ticker | Price | Mkt Cap | EV/EBITDA | Fwd P/E | Rev Growth | Gross Margin | FCF Yield |
|---|---|---|---|---|---|---|---|
ISRGINTUITIVE SURGICAL INC | $372.60 | $133.5B | 32.3x | 34.5x | +20.7% | 66.7% | 2.4% |
Company Profile
About the Company
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.
Next Earnings Date
Oct 20, 2026
Loading latest news...